Hemoglobin A1c in hemodialysis patients: Should one size fit all?

Clinical Journal of the American Society of Nephrology

Volumn 5, Issue 9, 2010, Pages 1539-1541

  Ix, Joachim H ^a,b,c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C;

ANEMIA; CARDIOVASCULAR RISK; COMORBIDITY; ERYTHROCYTE LIFESPAN; FOLLOW UP; GLUCOSE BLOOD LEVEL; HAZARD RATIO; HEALTH CARE FACILITY; HEMODIALYSIS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; MALNUTRITION; MORTALITY; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PATIENT CARE; POST HOC ANALYSIS; RETINOPATHY; REVIEW; UNITED STATES; VASCULAR ACCESS;

BIOLOGICAL MARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY FAILURE, CHRONIC; NUTRITIONAL STATUS; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; RENAL DIALYSIS; RISK ASSESSMENT; RISK FACTORS; SERUM ALBUMIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 77957306703     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.04410510     Document Type: Review

References (29)

1. Collins AJ, Foley RN, Herzog C, Chavers BM, Gilbertson D, Ishani A, Kasiske BL, Liu J, Mau LW, McBean M, Murray A, St Peter W, Guo H, Li Q, Li S, Li S, Peng Y, Qiu Y, Roberts T, Skeans M, Snyder J, Solid C, Wang C, Weinhandl E, Zaun D, Arko C, Chen SC, Dalleska F, Daniels F, Dunning S, Ebben J, Frazier E, Hanzlik C, Johnson R, Sheets D, Wang X, Forrest B, Constantini E, Everson S, Eggers PW, Agodoa L: Excerpts from the US Renal Data System 2009 Annual Data Report. Am J Kidney Dis 55[Suppl 1]: S1-S420, 2010
2. Kidney Disease: Improving Global Outcomes (KDIGO). Available online at http://www.kdigo.org. Accessed May 18, 2010
3. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis 49[Suppl 2]: S12-S154, 2007 (Pubitemid 46185743)
4. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B: Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 29: 1963-1972, 2006
5. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B: Management of hyperglycaemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 49: 1711-1721, 2006 (Pubitemid 44025023)
6. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353: 238-248, 2005 (Pubitemid 41058323)
7. Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Gronhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Suleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wuthrich RP, Gottlow M, Johnsson E, Zannad F: Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360: 1395-1407, 2009
8. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358: 2545-2559, 2008 (Pubitemid 351831356)
9. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358: 2560-2572, 2008 (Pubitemid 351831357)
10. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD: Glucose control and vascular complications in veterans with type 2 Diabetes. N Engl J Med 360: 129-131, 2008
11. Hasslacher C, Wittmann W: [Severe hypoglycemia in diabetics with impaired renal function] (in German). Dtsch Med Wochenschr 128: 253-256, 2003
12. Muhlhauser I, Toth G, Sawicki PT, Berger M: Severe hypoglycemia in type I diabetic patients with impaired kidney function. Diabetes Care 14: 344-346, 1991
13. Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356: 2457-2471, 2007 (Pubitemid 46919772)
14. Singh S, Loke YK, Furberg CD: Long-term risk of cardiovascular events with rosiglitazone: A meta-analysis. JAMA 298: 1189-1195, 2007 (Pubitemid 47403105)
15. Williams ME, Lacson E, Wang W, Lazarus JM, Hakim R: Glycemic control and extended hemodialysis survival in patients with diabetes mellitus: Comparative results of traditional and time-dependent Cox model analyses. Clin J Am Soc Nephrol 5: 1595-1601, 2010
16. Williams ME, Lacson E Jr, Teng M, Ofsthun N, Lazarus JM: Hemodialyzed type I and type II diabetic patients in the US: Characteristics, glycemic control, and survival. Kidney Int 70: 1503-1509, 2006 (Pubitemid 44527322)
17. Kalantar-Zadeh K, Kopple JD, Regidor DL, Jing J, Shinaberger CS, Aronovitz J, McAllister CJ, Whellan D, Sharma K: A1C and survival in maintenance hemodialysis patients. Diabetes Care 30: 1049-1055, 2007 (Pubitemid 46684623)
18. Drechsler C, Krane V, Ritz E, Marz W, Wanner C: Glycemic control and cardiovascular events in diabetic hemodialysis patients. Circulation 120: 2421-2428, 2009
19. Joy MS, Cefalu WT, Hogan SL, Nachman PH: Long-term glycemic control measurements in diabetic patients receiving hemodialysis. Am J Kidney Dis 39: 297-307, 2002 (Pubitemid 34174252)
20. Feldt-Rasmussen B: Is there a need to optimize glycemic control in hemodialyzed diabetic patients? Kidney Int 70: 1392-1394, 2006 (Pubitemid 44527307)
21. Nagayama H, Inaba M, Okabe R, Emoto M, Ishimura E, Okazaki S, Nishizawa Y: Glycated albumin as an improved indicator of glycemic control in hemodialysis patients with type 2 diabetes based on fasting plasma glucose and oral glucose tolerance test. Biomed Pharmacother 63: 236-240, 2009
22. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ: Translating the A1C assay into estimated average glucose values. Diabetes Care 31: 1473-1478, 2008
23. Nathan DM, Turgeon H, Regan S: Relationship between glycated haemoglobin levels and mean glucose levels over time. Diabetologia 50: 2239-2244, 2007 (Pubitemid 47512407)
24. Rajagopalan S, Dellegrottaglie S, Furniss AL, Gillespie BW, Satayathum S, Lameire N, Saito A, Akiba T, Jadoul M, Ginsberg N, Keen M, Port FK, Mukherjee D, Saran R: Peripheral arterial disease in patients with end-stage renal disease: Observations from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Circulation 114: 1914-1922, 2006
25. Eggers PW, Gohdes D, Pugh J: Nontraumatic lower extremity amputations in the Medicare end-stage renal disease population. Kidney Int 56: 1524-1533, 1999 (Pubitemid 29451259)
26. Huijbregts HJ, Bots ML, Wittens CH, Schrama YC, Moll FL, Blankestijn PJ: Hemodialysis arteriovenous fistula patency revisited: Results of a prospective, multicenter initiative. Clin J Am Soc Nephrol 3: 714-719, 2008
27. Teehan GS, Bahdouch D, Ruthazer R, Balakrishnan VS, Snydman DR, Jaber BL: Iron storage indices: Novel predictors of bacteremia in hemodialysis patients initiating intravenous iron therapy. Clin Infect Dis 8: 1090-1094, 2004 (Pubitemid 38951253)
28. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 329: 977-986, 1993
29. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352: 837-853, 1998